Cantargia is a clinical stage biotechnology company based in Sweden, established in 2009 and listed on Nasdaq Stockholm main market. It is developing two antibodies against IL1RAP, nidanilimab (CAN04) and CANxx. Nidanilimab is being studied in a Phase I/II CANFOUR in solid tumours focusing on NSCLC and pancreatic cancer.
Cantargia is developing two antibodies against IL1RAP: Nidanilimab (CAN04) and CANxx. Nidanilimab is currently being studied in a Phase I/II CANFOUR trial where the Phase I part focuses on several solid tumours, and the Phase II part focuses on NSCLC and pancreatic cancer. The Phase I data (n = 22) were presented at ASCO 2019 and demonstrated a good nidanilimab’s safety profile and a positive effect on biomarkers. The Phase II part of the study is now enrolling patients. Nidanilimab has a dual mechanism of action: inhibition of IL-1 signaling and antibody-dependent cellular cytotoxicity (ADCC). Novartis is conducting three Phase III trials in NSCLC with canakinumab (IL-1beta antibody) following some intriguing results from its six-year Phase III cardiovascular outcomes study in heart attack patients. Cantargia has recently raised SEK106m (gross) in a directed share issue.
Increasing the understanding of inflammation in malignant process now includes findings that cytokines are not only produced by the immune cells, but also cancer itself could produce certain cytokines and the associated receptors to escape from the immune response. Therefore, cytokines represent potentially promising class of targets in cancer management.